Revamped Schedule M Set to Boost Pharma Exports Pharmexcil DG

The country will take decisive action for standard improvement with its Revised Schedule M norms. This Revised Schedule M system will promote quality standards within the pharmaceutical industry, making it a growth tool for Indian exports to the world market. 

This first-of-its-kind endeavor points out the relentlessness of the Indian government about composite regulations surrounding the pharmaceutical manufacturing right from a safety and efficacy point of view, which is the birthright of a vibrant export industry, said Uday Bhaskar, the DG of the Pharmaceuticals Export Promotion Council of India (Pharmexcil).

He was at the sideline of the one-day training workshop organized by Pharmexcil in collaboration with the Goa Drugs Administration (FDA) and Central Drugs Standard Control Organisation (CDSCO) at Panjim, Goa, on March 27, 2024.

Highlighting the new Schedule M norms lotion as a turning point in the quest for supremacy of quality in the medical sphere, he stressed that these rules will act as a catalyst for the nurturing of a culture centering around paying attention to little details as well as continuous improvement, which is considered to be crucial for India to become a worthy supplier of quality medicines to more than two hundred countries.

When an industry has to look against the backdrop of regulatory tightening, the exports of India's pharmaceuticals are amongst the segments that benefit immensely and have rocketed almost 10% between April to February fiscal year 2023-24. In particular, sales to the United States, more important to Indian pharmaceuticals, have recorded splendid growth figures of almost 15 percent or more in the same time frame being discussed.